Biophytis S.A.

ENXTPA:ALBPS Stock Report

Market Cap: €1.6m

Biophytis Valuation

Is ALBPS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALBPS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALBPS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALBPS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALBPS?

Key metric: As ALBPS is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ALBPS. This is calculated by dividing ALBPS's market cap by their current book value.
What is ALBPS's PB Ratio?
PB Ratio-0.2x
Book-€6.38m
Market Cap€1.57m

Price to Book Ratio vs Peers

How does ALBPS's PB Ratio compare to its peers?

The above table shows the PB ratio for ALBPS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.1x
ALINT IntegraGen
1.5xn/a€2.9m
ALTME TME Pharma
4.1xn/a€6.4m
ALVET TheraVet
0.05xn/a€285.5k
ALVIO Valerio Therapeutics Société anonyme
3xn/a€11.9m
ALBPS Biophytis
n/an/a€1.6m

Price-To-Book vs Peers: ALBPS has negative equity and a Price-To-Book Ratio (-0.2x) compared to the peer average (2.1x).

Price to Book Ratio vs Industry

How does ALBPS's PB Ratio compare vs other companies in the FR Biotechs Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
ALVET TheraVet
0.05xn/aUS$297.34k
ALNEV Neovacs
0.0001xn/aUS$1.94k
No more companies available in this PB range
ALBPS is unprofitableIndustry Avg. 1.9xNo. of Companies3PB012345+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ALBPS has negative equity and a Price-To-Book Ratio (-0.2x) compared to the French Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is ALBPS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALBPS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-0.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ALBPS's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sanofi

€116.8b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€93.17

7D

2.0%

1Y

7.9%

Theranexus Société Anonyme

€3.9m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.50

7D

0%

1Y

-57.2%

Eurofins Scientific

€8.9b

Provides various analytical testing and laboratory services worldwide.

ERF

€46.96

7D

3.3%

1Y

-12.0%